Results 321 to 330 of about 2,888,163 (384)

C-C Motif chemokine receptor-2 blockade ameliorates pulmonary hypertension in rats and synergizes with a pulmonary vasodilator. [PDF]

Cardiovasc Res
Tsuboya N, Sawada H, Mitani Y, Oshita H, Ohya K, Takeoka M, Kabwe JC, Miyasaka Y, Ito H, Yodoya N, Ohashi H, Maruyama J, Okamoto R, Mashimo T, Dohi K, Nishimura Y, Maruyama K, Hirayama M.   +17 more
europepmc   +1 more source

Mechanisms and Recent Advances of Small-Molecule Therapeutics in Rosacea Treatment. [PDF]

Clin Cosmet Investig Dermatol
Ye M, Hao P, Luo N, Li T.
europepmc   +1 more source

A multifaceted examination of the action of PDE4 inhibitor rolipram on MMP2/9 reveals therapeutic implications. [PDF]

Sci Rep
Bagchi A, Roy A, Halder A, Biswas A.
europepmc   +1 more source

What's new in the 2025 GOLD report. [PDF]

J Bras Pneumol
Halpin DMG, Singh D.
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Crisaborole: Phosphodiesterase inhibitor for treatment of atopic dermatitis.

Drugs of Today, 2017
Atopic dermatitis (AD) is an extremely common condition affecting as many as 10-20% of children and 2-10% of adults. A particularly distressing symptom of AD is pruritus.
D. Paton
semanticscholar   +1 more source

Electrophysiology of phosphodiesterase inhibitors

The American Journal of Cardiology, 1989
Phosphodiesterase inhibitors appear to uniformly enhance atrioventricular node conduction, although milrinone seems to have the least effect. Except for digoxin, this effect on atrioventricular node conduction is similar to that noted with other inotropic agents.
Richard A. Goldstein, Gerald V. Naccarelli   +1 more
openaire   +3 more sources